Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855385 | 0.83 | XPO1 (0.43) | XPO1POLBLMNA | |
| SCHEMBL857395 | 0.79 | HDAC3 (0.40) | KMT2AMEN1MAPTSMN1; SMN2POLB | |
| SCHEMBL5432959 | 0.78 | CYP1A2 (0.53) | XPO1KMT2AMEN1MAPTHPGD | |
| SCHEMBL2432545 | 0.78 | MAPT (0.46) | KMT2AMEN1MAPTSMN1; SMN2POLB | |
| SCHEMBL534133 | 0.75 | SYK (0.47) | KMT2AMEN1MAPTSMN1; SMN2POLB | |
| SCHEMBL30864787 | 0.75 | SYK (0.47) | KMT2AMEN1MAPTSMN1; SMN2POLB | |
| SCHEMBL18611252 | 0.74 | XPO1 (0.46) | XPO1 | |
| SCHEMBL671079 | 0.74 | POLQ (0.45) | KMT2AMEN1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL20496807 | 0.74 | MAPT (0.45) | MAPTSMN1; SMN2CYP1A2HSD17B10LMNA | |
| SCHEMBL17653827 | 0.74 | POLB (0.46) | KMT2AMEN1MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060058356-A1 | Indolylmaleimide derivatives | NOVARTIS AG | 2006-03-16 | — | — | US | disclosed |
| EP-1597250-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058356-A1 | Indolylmaleimide derivatives | GSK3B, GSK3A, GSKIP | XPO1 2257/4885KMT2A 1839/4885MEN1 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.